GLP-1 medications have made meaningful weight loss achievable for many people, but the question increasingly being asked is what happens when treatment reduces or stops. NICE now recommends ongoing support and monitoring after weight-management medication ends, but structured pathways for that transition are thin on the ground.
BMeals is building software to help people move from medication-led weight loss to behaviour-led maintenance, translating high-touch coaching principles into something providers can deliver at scale.
Boston Freestone is BMeals’ Founder and CEO. His background is in biomedical science and sports nutrition, and he’s spent over 10 years coaching 600+ people through weight loss and long-term maintenance. We spoke about the post-GLP-1 support gap and why the company is careful not to overclaim what the technology can do.
Can you introduce yourself and tell us about your role?
I’m Boston Freestone, Founder & CEO of BMeals. My background is in biomedical science, sport & exercise physiology, sports nutrition and 10+ years of coaching people through weight loss and long-term weight maintenance. I’ve coached 600+ clients and also went through my own major weight-loss transformation as a teenager.
My role at BMeals is to lead the product vision, commercial strategy, research/evidence pathway and partnerships, bringing together the clinical, technical and user insight needed to build the platform.
How did your company come about and what was the motivation behind it?
BMeals came from two things I kept seeing over and over. First, I lost a significant amount of weight myself as a teenager and have spent the last 10+ years coaching 600+ people through weight loss and, more importantly, trying to keep it off long term. That made long-term weight maintenance the part of the problem I became most interested in.
More recently, more GLP-1 users started appearing in my high-touch coaching business. The problem was obvious: they often needed support around food structure, appetite returning, weight monitoring and what happens as medication changes – but high-touch coaching is expensive and impossible to scale to everyone.
BMeals started as the software answer to that scalability problem: translating the repeatable support principles I was using manually into something providers could deliver at scale.
As the product and discovery work progressed, the clearest wedge became the transition from medication-led weight loss to behaviour-led maintenance – particularly during tapering, stopping and post-GLP-1 support. That is now the core direction of BMeals.
Can you describe your company’s mission and values?
Our mission is to help more people experience the benefits of good nutrition and sustain weight loss long term – ultimately contributing to reducing the wider burden of obesity.
BMeals is starting with one clear gap: helping people move from medication-led weight loss to behaviour-led maintenance.
Our values are evidence over hype, empathy for the individual, accessibility, continuous learning and responsible innovation. We want to build support that is practical, scalable and genuinely useful – without overclaiming what the technology can do.
What are some of the most pressing social issues that your company is working to address through its technology?
The rapid growth of GLP-1 medication is creating a new social challenge: people can achieve meaningful weight loss with medication, but many are now asking what happens when treatment reduces or stops. Our own discovery work repeatedly found fear of weight regain, appetite and food noise returning, and a lack of structured support after stopping.
This gap is increasingly being recognised formally: NICE now recommends ongoing support and monitoring after weight-management medication is stopped, reinforcing that the transition itself needs a proper support pathway.
BMeals is trying to address that gap by helping people move from medication-led weight loss toward behaviour-led maintenance, without requiring everyone to stay in expensive one-to-one coaching. The wider aim is to make structured nutrition, weight monitoring and maintenance support more scalable and accessible, while recognising that private-first evidence will not automatically represent more deprived or NHS populations and will need broader validation over time.
How does your company measure the impact of its work in creating positive change?
BMeals is still early-stage, so we are not claiming clinical impact yet. Our first measure of positive change is whether the support is usable, acceptable, engaging and fits safely into existing care pathways. We also plan to measure user confidence around food as medication changes, engagement and data completeness, provider acceptability, staff support time per user, routine support contacts and cost per engaged user. Longer term, feasibility work may track weight trajectory, appetite, food noise, eating confidence and maintenance behaviours, before progressing to comparative clinical outcomes.
In your opinion, what impact will technology have in creating a better future?
I believe technology can make good support far more scalable, continuous and accessible. In health, the opportunity is not to replace clinicians, but to extend support beyond appointments – helping people act on the right information at the right time and giving providers better visibility of what is happening between reviews.
For BMeals, that means turning high-touch nutrition and weight-maintenance support into something that can reach far more people, while collecting better-quality data to improve the pathway over time. If done responsibly, with clear safety boundaries and human oversight, technology can help move healthcare from episodic intervention toward earlier, more continuous and preventative support.
What advice do you have for other companies looking to use technology for good and create a positive impact in the world?
There’s no good in playing small. Positively disrupt – even if you get under a few people’s skin.
—
BMeals is early-stage and not claiming clinical impact yet. Their first measure is whether the support is usable, acceptable and fits safely into existing care pathways. Longer-term outcomes will follow. You can find out more at bmeals.ai.
BMeals is pitching at the Manchester Health Series powered by Empact Ventures supported by Global Good
